12 Month Price Forecast For GERN
Distance to GERN Price Forecasts
GERN Price Momentum
๐ค Considering Geron (GERN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 8:08 AM UTC
GERN Analyst Ratings & Price Targets
Based on our analysis of 17 Wall Street analysts, GERN has a bullish consensus with a median price target of $8.00 (ranging from $6.00 to $10.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $2.82, the median forecast implies a 183.7% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Tara Bancroft at TD Cowen, projecting a 254.6% upside. Conversely, the most conservative target is provided by Gil Blum at Needham, suggesting a 112.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GERN Analyst Consensus
GERN Price Target Range
Latest GERN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GERN.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 13, 2025 | Needham | Gil Blum | Buy | Maintains | $7.00 |
Dec 13, 2024 | Needham | Gil Blum | Buy | Reiterates | $6.00 |
Dec 10, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $9.00 |
Nov 6, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
Nov 5, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Initiates | $8.00 |
Oct 16, 2024 | Scotiabank | Greg Harrison | Sector Outperform | Initiates | $6.00 |
Sep 9, 2024 | Leerink Partners | Faisal Khurshid | Outperform | Initiates | $7.00 |
Aug 9, 2024 | Needham | Gil Blum | Buy | Reiterates | $6.00 |
Jul 26, 2024 | Needham | Gil Blum | Buy | Reiterates | $6.00 |
Jun 11, 2024 | Barclays | Carter Gould | Overweight | Initiates | $9.00 |
Jun 10, 2024 | Barclays | Overweight | Initiates | $9.00 | |
Jun 10, 2024 | Stifel | Stephen Willey | Buy | Maintains | $7.00 |
Jun 7, 2024 | Needham | Gil Blum | Buy | Maintains | $6.00 |
Jun 7, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $7.00 |
May 2, 2024 | Needham | Gil Blum | Buy | Reiterates | $5.00 |
Apr 30, 2024 | Baird | Joel Beatty | Neutral | Downgrade | $4.50 |
Apr 29, 2024 | TD Cowen | Tara Bancroft | Buy | Initiates | $10.00 |
Apr 11, 2024 | Needham | Gil Blum | Buy | Reiterates | $5.00 |
Apr 10, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $6.00 |
Mar 15, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $6.00 |
Stocks Similar to Geron Corp
The following stocks are similar to Geron based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Geron Corp (GERN) Financial Data
Geron Corp has a market capitalization of $1.68B with a P/E ratio of -8.8x. The company generates $29.48M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +17,138.4% quarter-over-quarter, while maintaining an operating margin of -99.8% and return on equity of -69.0%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Geron Corp (GERN) Company Overview
About Geron Corp
Develops therapeutics for blood cancers.
Geron Corporation operates as a late-stage clinical biopharmaceutical company, primarily focusing on developing imetelstat, a telomerase inhibitor. The company generates revenue through the commercialization of its therapeutics, particularly as it progresses through clinical trials and potentially gains regulatory approvals.
Founded in 1990 and based in Foster City, California, Geron is currently in Phase 3 clinical trials for imetelstat, targeting specific blood disorders such as myelodysplastic syndromes and myelofibrosis. Its focus on myeloid hematologic malignancies positions it in a niche market with potential for high impact treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
141
CEO
Dr. John A. Scarlett M.D.
Country
United States
IPO Year
1996
Website
www.geron.comGeron Corp (GERN) Latest News & Analysis
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
8 days agoGeron Corporation (Nasdaq: GERN) will release its Q4 and full-year 2024 financial results on February 26, 2025, and host a conference call at 8:00 a.m. ET to discuss them.
Geron Corporation's upcoming financial results release and conference call may influence stock performance and investor sentiment, providing insights into its business health and future prospects.
GERN's Rytelo, approved in mid-2024, reported Q3'24 revenues of $28.2M and projected Q4'24 revenues of $45M-$46M. EU approval for lower-risk myelodysplastic syndromes is anticipated in H1'25.
Rytelo's strong early sales and upcoming EU approval could drive GERN's growth, mitigating market exclusivity concerns and positioning the company favorably for future revenue.
Geron Corporation granted equity awards totaling 312,000 shares, including 208,000 stock options and 104,000 RSUs, to three new employees as an inducement for their employment.
Geron Corporation's equity awards to new employees signal confidence in growth and talent acquisition, potentially enhancing its operational capabilities and future performance, impacting stock value.
Geron Corporation's RYTELO received FDA approval for Low-Risk Myelodysplastic Syndrome and is pending EMA approval. Q3 sales reached $28.2M; Q4 2024 projections are $45-$46M. Phase 3 study results expected by 2027.
FDA approval for RYTELO may lead to increased sales, with projections rising and ongoing studies enhancing future growth potential, positively impacting Geron's stock value.
FDA approved GERN's Rytelo (imetelstat) for low- to intermediate-1 risk MDS, boosting the stock by 61.1% over the past year.
FDA approval boosts GERN's market confidence and potential revenue, driving stock value up significantly, indicating strong investor interest and positive future outlook.
Geron Corporation's RYTELO (imetelstat) received a positive opinion from the EMA's CHMP for treating transfusion-dependent anemia in adult patients with myeloma.
Geron Corporation's positive opinion from the EMA for RYTELO could lead to market approval, enhancing revenue potential and investor confidence in the company's future growth.
Frequently Asked Questions About GERN Stock
What is Geron Corp's (GERN) stock forecast for 2025?
Based on our analysis of 17 Wall Street analysts, Geron Corp (GERN) has a median price target of $8.00. The highest price target is $10.00 and the lowest is $6.00.
Is GERN stock a good investment in 2025?
According to current analyst ratings, GERN has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for GERN stock?
Wall Street analysts predict GERN stock could reach $8.00 in the next 12 months. This represents a 183.7% increase from the current price of $2.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Geron Corp's business model?
Geron Corporation operates as a late-stage clinical biopharmaceutical company, primarily focusing on developing imetelstat, a telomerase inhibitor. The company generates revenue through the commercialization of its therapeutics, particularly as it progresses through clinical trials and potentially gains regulatory approvals.
What is the highest forecasted price for GERN Geron Corp?
The highest price target for GERN is $10.00 from Tara Bancroft at TD Cowen, which represents a 254.6% increase from the current price of $2.82.
What is the lowest forecasted price for GERN Geron Corp?
The lowest price target for GERN is $6.00 from Gil Blum at Needham, which represents a 112.8% increase from the current price of $2.82.
What is the overall GERN consensus from analysts for Geron Corp?
The overall analyst consensus for GERN is bullish. Out of 17 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are GERN stock price projections?
Stock price projections, including those for Geron Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.